1 / 8

TRATAMIENTO DEL DOLOR EN NEUROPATIA DIABETICA

TRATAMIENTO DEL DOLOR EN NEUROPATIA DIABETICA. Acido alpha lipoico Oral Treatment With -Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy . The SYDNEY 2 trial Diabetes Care 29:2365-2370, 2006

taurean
Télécharger la présentation

TRATAMIENTO DEL DOLOR EN NEUROPATIA DIABETICA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TRATAMIENTO DEL DOLOREN NEUROPATIA DIABETICA

  2. Acido alpha lipoico • Oral Treatment With -Lipoic Acid Improves Symptomatic DiabeticPolyneuropathy. The SYDNEY 2 trial Diabetes Care 29:2365-2370, 2006 Oral treatment with ALA for 5 weeks improvedneuropathic symptoms and deficits in patients with DSP. An oraldose of 600 mg once daily appears to provide the optimum risk-to-benefitratio • Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV: Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 111:343–348, 2005 In the Irbesartan and Lipoic Acid in Endothelial Dysfunction(ISLAND) study, oral administration of 300 mg ALA per day asmonotherapy and in combination with irbesartan (150 mg/day)to patients with the metabolic syndrome resulted in a significantincrease in endothelium-dependent flow-mediated vasodilationof the brachial artery by 44 and 75%, respectively, comparedwith placebo treatment after 4 weeks. This effect was accompaniedby reductions in plasma levels of interleukin-6 and plasminogenactivator-1, suggesting that the drug may improve endothelialdysfunction via anti-inflammatory and antithrombotic mechanisms • Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler HT, Low PA: Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18:1160–1167, 1995

  3. Acetyl-L-carnitineimproves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials.Sima AA, Calvani M, Mehra M, Amato A; Acetyl-L-Carnitine Study Group.Diabetes Care. 2005 Jan;28(1):89-94.1000 pacientes 500 – 1000mg/d por 52 semanas Acetyl-L-carnitinein the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study.De Grandis D, Minardi C.Drugs R D. 2002;3(4):223-31. Benfotiaminein the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). Haupt E, Ledermann H, Köpcke W.Int J Clin Pharmacol Ther. 2005 Jun;43(6):304. Prodroga vit B1 liposoluble

More Related